单克隆抗体,英文名monoclonal antibody,缩写是mAb,简称单抗。这是一类由同种免疫细胞制造出来的抗体,相对应的另一类抗体叫“多克隆抗体”(polyclonal antibody),是一类由多种浆细胞产生的多种抗体混合物。 在癌症的治疗中,单克隆抗体药物的中文名通常以“单抗”结尾,英文名通常以“-mab”结尾。根据来源,目前癌症治疗...
PROBLEM TO BE SOLVED: To provide antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, and hepatocellular cancer.SOLUTION: An antibody has ...
The “magic bullet” era of targeted cancer therapy began with the United States Food and Drug Administration approval of rituximab for the treatment of B-cell lymphoma in the late fall of 1997. Since then, several additional anticancer antibody products have received regulatory approval, including ...
Monoclonal antibodies have revolutionized the treatment of several human diseases, including cancer, autoimmunity and inflammatory conditions and represent a new frontier for the treatment of infectious diseases. In the last decade, new methods have allowed the efficient interrogation of the human antibody...
The Ec peptide (PEc) that defines the IGF-1Ec isoform, is associated with prostate cancer progression by inducing proliferation, metastases, and tumour repair. On these grounds, an anti-PEc monoclonal antibody (MAb) was developed. Our objective is to examine the effects of this antibody on pro...
Monoclonal antibodies (mAbs) that regulate the immune response are now being clinically evaluated as anticancer agents. This Review discusses their progress to date and the possibilities for combining these antibodies with other cancer treatments. Increa
A protein-based monoclonal human antibody, including amino acid sequences identical or substantially identical to those represented by some peptides or salts of FDA No. 1 or 3, as an effective means of cancer prevention / treatment. An inducer for cancer cell necrosis, an inhibitor for inhibitin...
Monoclonal Antibody (mABs) Therapeutics Market by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Forecast to 2029 ...
J. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J. Clin. Oncol. 26, 5275–5283 (2008). Article CAS PubMed Google Scholar Maker, A. V., Attia, P. & Rosenberg, S. A. Analysis of the cellular ...
antibodies approved by the FDA or currently undergoing clinical trials, and reveal the binding modes of the complexes and the conformational changes induced by the antibody binding, thereby providing a structural basis of checkpoint blockade by monoclonal antibodies for the treatment of cancer. ...